US 10,143,270

Application 14/400,035 · Granted Dec 4, 2018

Closure device for releasably connecting two parts

Estimated expiration

February 19, 2035

8y 92d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
  • Could not fetch continuity data for application PCTEP2013076331: Resource not found (404)
Earliest effective filing
Dec 12, 2013
+ 20 years
Dec 12, 2033
PTA +434d
Feb 19, 2035
No TD
—
Final
Feb 19, 2035

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
November 10, 2014
Earliest effective filing
December 12, 2013
Issue date
December 4, 2018
PTA
+434 days
Base expiry (before PTA)
December 12, 2033

December 12, 2013 + 20 years = December 12, 2033 + 434 PTA days = February 19, 2035

  • National stage entry of application PCTEP2013076331, filed Dec 12, 2013

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 14/400,035 · US 10,143,270

PatentReply compiles the prosecution history behind US 10,143,270: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US10143270

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.